AcknowledgmentsIn addition to the members of the Task Force, there have been a number of people whose contribution to theseguidelines has been invaluable. First, we would like to thank Dr. Robert Vigersky, the members of the ClinicalGuidelines Subcommittee, the Clinical Affairs Core Committee, and the Council of <strong>The</strong> <strong>Endocrine</strong> <strong>Society</strong> fortheir careful reading of and very useful suggestions for improving the guidelines. Second, we thank the membersof <strong>The</strong> <strong>Endocrine</strong> <strong>Society</strong> at large for their input when the draft guidelines were posted on the <strong>Society</strong>’s website;all the responses received were considered by the authors, and many incorporated. Third, we thank the membersof our sister societies around the world for their enthusiastic involvement in reading the draft guidelines, and inoffering their support for this publication. Fourth, we thank Lisa Marlow of <strong>The</strong> <strong>Endocrine</strong> <strong>Society</strong>, who hasprovided first-class administrative and logistic back-up, without which such a geographically disperse task forcewould have faced considerable difficulty in operating. Last, but very much not least, the authors are indebted toDr. Patricia A. Stephens, medical writer, for her unfailing patience, her meticulous checking of both text andreferences, and most importantly her ability to meld half a dozen disparate writing styles into a seamless whole.Financial Disclosure of Task ForceTHE ENDOCRINE SOCIETY’S CLINICAL <strong>GUIDELINES</strong>John W. Funder, MD, PhD (chair)—Financial or Business/Organizational Interests: Schering-Plough, Daiichi-Sankyo, Pfizer, Cancer Institute of N.S.W, Speedel, Garnett Passe and Rodney Williams Memorial Foundation,Merck, Eli Lilly, P3 Panel (Commonwealth of Australia); Significant Financial Interest or Leadership Position:Schering-Plough, Pfizer, Daiichi-Sankyo and Cancer Institute of N.S.W. Robert M. Carey, MD—Financial orBusiness/Organizational Interests: Novartis, Pfizer, Daiichi-Sankyo; Significant Financial Interest or LeadershipPosition: none declared. Carlos Fardella, MD—Financial or Business/Organizational Interests: National Fund forScientific and Technological Development (Fondo Nacional de Desarrollo Científico y Tecnológico[FONDECYT]); Significant Financial Interest or Leadership Position: none declared. Celso E. Gomez-Sanchez,MD—Financial or Business/Organizational Interests: American Heart Association; Significant Financial Interestor Leadership Position: Associate Editor for the journal Hypertension. Franco Mantero, MD, PhD—Financial orBusiness/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: ExecutiveCommittee of the International <strong>Society</strong> of Endocrinology. Michael Stowasser, MBBS, FRACP, PhD—Financialor Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: nonedeclared. William F. Young Jr., MSc, MD—Financial or Business/Organizational Interests: none declared;Significant Financial Interest or Leadership Position: Mayo Clinic, Clinical Endocrinology. *Victor M. Montori,MD—Financial or Business/Organizational Interests: KER Unit (Mayo Clinic); Significant Financial Interest orLeadership Position: none declared.*Evidence-based reviews for this guideline were prepared under contract with <strong>The</strong> <strong>Endocrine</strong> <strong>Society</strong>.26
THE ENDOCRINE SOCIETYGUIDELINE ORDER FORM(Single reprint request for orders of 100 and less)8401 Connecticut Avenue, Suite 900Chevy Chase, MD 20815-5817Phone 301.941.0210; Fax 301.941.0257societyservices@endo-society.orgFEIN 73-0521256PRODUCTS QTY. PRICE (USD) SUBTOTALMemberNon-MemberAndrogen <strong>The</strong>rapy in Women: $15.00 $20.00An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice GuidelineCase Detection, Diagnosis, and Treatment of Patients with Primary $15.00 $20.00Aldosteronism: An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice Guideline<strong>The</strong> Diagnosis of Cushing’s Syndrome: $15.00 $20.00An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice GuidelineEvaluation & Treatment of Adult Growth Hormone Deficiency: $15.00 $20.00An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice GuidelineEvaluation & Treatment of Hirsutism in Premenopausal Women: $15.00 $20.00An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice GuidelineManagement of Thyroid Dysfunction during Pregnancy and Executive Summary Executive SummaryPostpartum: An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice Guideline (MMTD07)—$10.00 (MMTD07)—$15.00Guideline (MTSD07)— Guideline (MTSD07)—$10.00 $15.00Testosterone <strong>The</strong>rapy in Adult Men with Androgen Deficiency $15.00 $20.00Syndromes: An <strong>Endocrine</strong> <strong>Society</strong> Clinical Practice GuidelineMiscellaneousTOTAL All prices include sales tax $PAYMENT INFORMATION: ❍ Check ❍ MasterCard ❍ VisaCard NumberExpiration DateBilling AddressSignatureAre you a member of <strong>The</strong> <strong>Endocrine</strong> <strong>Society</strong>? ❍ Yes ❍ NoIf you are a member and you know your member ID, please provide: ___________________________________________________________Prefix: First Name (Given): Middle: Last (Surname):Institution/Company:Dept/Div:Street/PO:City: State/Province: Zip/Mail Code: Country:Telephone: Fax: Email:Degree(s) that you would like listed after your name: Professional Title: Date of Birth: Gender:❍ Male❍ FemaleWhich of the following best describes your primary professional role?Race or Ethnic Affiliation (voluntary)(Please mark only one)❍ African American, Black❍ Administrator ❍ Retired ❍ Asian❍ Basic Researcher ❍ Teacher/Educator ❍ Hispanic❍ Clinical Practitioner ❍ Fellow (Clinical) ❍ Native American, Eskimo, Aleut❍ Clinical Researcher ❍ Fellow (Postdoctoral/Research) ❍ Pacific Islander❍ Industry/Corporate Professional ❍ Student ❍ White, Caucasian❍ Nurse/Healthcare Professional ❍ Other___________________________________ ❍ Other___________________________________
Change language